BSECompany Update3d ago · 6 Nov 2026, 07:22 pm

Undertaking for Non-Applicability of Regulation 32 of SEBI (LODR)

Kabra Drugs Ltd · 524322

✦ AI SummaryRegulatory

Kabra Drugs Ltd, formerly known as Aanjaay Industries Ltd, has submitted an undertaking to BSE stating that Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable for the quarter ended on 30th September 2026 as the company has not issued any shares through public issue, rights issue, or preferential issue.

Analysis Scores

Earnings Impact1/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact1/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Kabra Drugs Ltd - 524322 - Undertaking For Non- Applicability Of Regulation 32 Of SEBI (LODR) Regulations, 2015 For The Quarter Ended On 30Th September 2026

Attachments (1)

📄

1fb9400f-8f06-47c0-9680-defd09df4585.pdf

pdf

Download →
View document text
Date: 06th November 2026 BSE Limited Phiroze Jeejeebhoy Towers 21st Floor, Dalal Street Mumbai – 400001 BSE Scrip Code: 524322 Sub: Undertaking for Non- Applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 for the quarter ended on 30 th September 2026 . Dear Sir/Madam, As per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) for quarter ended on 30th September 2026 for public issue, rights issue, preferential issue etc. – (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable; (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds. In view of the aforesaid, I, the undersigned, Mr. Nanjappan Aravind, Managing Director of Aanjaay Industries Limited (Formerly known as Kabra Drugs Limited) hereby certify that Compliances of Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company as the company has not issued any share by way of public issue, right issue, preferential issue etc. for the quarter ended on 30th September 2026. Kindly take the aforesaid information on record and oblige. Thanking you, Yours sincerely, For Aanjaay Industries Limited (Formerly known as Kabra Drugs Limited) Nanjappan Aravind Managing Director DIN: 01895602